Advertisement
RayBiotech
RayBiotech

Nesiritide and CHF

NEW YORK, July 27 (Praxis Press) Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has beneficial hemodynamic effects in patients with decompensated congestive heart failure (CHF). Colucci and colleagues assessed the clinical use of nesiritide in CHF patients to evaluate symptomatic endpoints. Patients hospitalized because of symptomatic CHF were enrolled in either an efficacy trial or a comparative trial. In the efficacy trial, 127 patients were randomly assigned to doub

July 31, 2000

NEW YORK, July 27 (Praxis Press) Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has beneficial hemodynamic effects in patients with decompensated congestive heart failure (CHF). Colucci and colleagues assessed the clinical use of nesiritide in CHF patients to evaluate symptomatic endpoints. Patients hospitalized because of symptomatic CHF were enrolled in either an efficacy trial or a comparative trial. In the efficacy trial, 127 patients were randomly assigned to double-blind treatment with placebo or nesiritide. In the comparative trial, 305 patients were randomly assigned to open-label therapy with standard agents or nesiritide for up to seven days. In the efficacy trial, nesiritide infusion resulted in improved global clinical status, reduced dyspnea, and reduced fatigue compared with placebo. In the comparative trial, the improvements in global clinical status, dyspnea, and fatigue were sustained with nesiritide therapy for up to seven days and were similar to those observed with standard intravenous therapy for heart failure. The most common side effect was dose-related hypotension, which was usually asymptomatic. In patients hospitalized with decompensated CHF, intravenous nesiritide improves clinical status as well as hemodynamic status.

Advertisement
Advertisement

Popular Now

  1. How Fats Influence the Microbiome
  2. Censored Professor Quits
    The Nutshell Censored Professor Quits

    Alice Dreger is resigning from the faculty of Northwestern University, claiming that the administration censored her work in a faculty journal.

  3. Opinion: Engineering the Epigenome
  4. Psychology’s Failure to Replicate
Advertisement
Bina
Bina
Advertisement
Life Technologies